GLUE
Monte Rosa Therapeutics, Inc. Common Stock
stockNASDAQ
small molecule protein degraders are set to reshape the way by which diseases will be treated. our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. headquartered in boston with additional laboratory facilities in basel, monte rosa therapeutics is a private company launched in 2020. initially seeded by versant ventures and incubated at ridgeline discovery in basel, and the institute of cancer research in london, monte rosa has raised $32.5 million from versant and new enterprise associates. academic co-founders are prof. raj chopra and prof. ian collins of the institute for cancer research, uk.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 10.57 | 2026-11-06 | -11.92% | 1.955 |
| 1M | 9.89 | 2026-10-13 | -5.87% | 1.188 |
| 3M | 15.84 | 2026-08-13 | -41.23% | 0.981 |
| 6M | 18.96 | 2026-05-13 | -50.90% | 0.725 |
| 1Y | 14.32 | 2025-11-13 | -34.99% | 0.959 |
| 2Y | 8.63 | 2024-11-13 | +7.88% | — |
| 5Y | 25.19 | 2021-11-12 | -63.04% | 1.564 |
Monte Rosa Therapeutics, Inc. Common Stock (NASDAQ:GLUE) stock price today is $9.31, and today's volume is 1,245,710. GLUE is down 9.699% today. The 30 day average volume is 1.52M. GLUE market cap is $795.54M with 85.45M shares outstanding.